# Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

> **NCT01314274** · PHASE2 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 15 (actual)

## Conditions studied

- HHT
- Morbus Osler
- Epistaxis

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** NaCl

## Key facts

- **NCT ID:** NCT01314274
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2013-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01314274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01314274, "Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01314274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*